Source comparison
CJC-1295 No DAC vs IGF-1 LR3 — Mechanism and Application Comparison
| Peptide | Primary Mechanism | Half-Life | Typical Dosing (Preclinical) | Experimental Applications | Regulatory Feedback | Bottom Line ||—|—|—|—|—|—|| CJC-1295 no DAC | GHRH analog. Binds pituitary GHRH receptors to stimulate endogenous GH release in pulses
This comparison does not assign a generated winner or score.
- | Peptide | Primary Mechanism | Half-Life | Typical Dosing (Preclinical) | Experimental Applications | Regulatory Feedback | Bottom Line ||—|—|—|—|—|—|| CJC-1295 no DAC | GHRH analog. Binds pituitary GHRH receptors to stimulate endogenous GH release in pulses | 30 min – 2 hours | 100–200 mcg SC, 1–3x daily | Neuroendocrine feedback studies, circadian GH rhythm models, hepatic IGF-1 production research | Yes. Negative feedback via IGF-1 and somatostatin | Best for models requiring intact hypothalamic-pituitary axis and physiological GH pulsatility || IGF-1 LR3 | Modified IGF-1 analog. Bypasses IGFBP binding and acts directly on tissue IGF-1 receptors | 20–30 hours | 20–100 mcg SC, once daily or every other day | Direct anabolic tissue studies, muscle protein synthesis models, localized receptor agonism | No. Bypasses GH-IGF-1 axis entirely | Best for studies requiring sustained IGF-1 receptor activation independent of pituitary function || Combination Use | CJC stimulates GH pulse; GH d
- This table should clarify the mechanism distinction immediately. The 'better' peptide depends entirely on whether your research model requires pituitary GH stimulation (CJC-1295 no DAC) or direct tissue receptor agonism (IGF-1 LR3). They are not functionally interchangeable.